Acetylcholinesterase

原鸦片碱（10–40 μM，24–96 小时）限制易位细胞（HepG2、Huh7）迁移、增殖和进行 EMT 的能力 [2]。 Protopine（10–40 μM，24 小时）抑制 PI3K/Akt 信号染料，并通过表达 caspase-3 和 caspase-9 导致 HepG2 和 Huh7 细胞中的细胞打开 [2]。原鸦片碱 (0–10 μg/mL) 抑制 S6 细胞和 N1 细胞中的血清素转运蛋白 (SERT) 功能，而原鸦片碱 (10–40 μM，6 小时) 会增加 HepG2 和 Huh7 细胞中活性氧 (ROS) 的形成。 3]。

原鸦片碱（0.1 和 1 mg/kg，腹腔注射）可以减轻东莨菪碱（1 mg/kg）引起的小鼠记忆障碍[1]。 Protropine (5-20 mg/kg，静脉注射) 可抑制肿瘤生长并抑制 PI3K/Akt，并在异种移植的 BALB/c 小鼠（皮下注射 HepG2 或 Huh-7 细胞）中诱导 caspase-3 通道 [2]。普拉托品（5-20 mg/kg，腹腔注射）在小鼠 HTR 和 TST 测试中显示出抗抑郁样作用 [3]。普托品（1-4 mg/kg，腹腔注射，每天一次，持续 3 天）对局灶性脑损伤具有保护作用[4]。

Protopine是一种异喹啉生物碱，具有多种生物活性，包括抗肿瘤活性。然而，普罗托品对肝癌细胞的影响仍然难以捉摸。本研究旨在检测普罗托品对肝癌细胞的体外和体内作用。 方法：采用MTT法测定细胞活力。进行伤口愈合和transwell检测以评估细胞的运动能力。流式细胞术检测细胞凋亡和ROS水平。Western印迹法用于测量蛋白质的变化。还评估了普罗托品在异种移植物小鼠中的细胞毒性。 结果：Protopine以半胱天冬酶依赖的方式通过内在途径抑制肝癌细胞的存活并触发凋亡。此外，普罗托品还诱导细胞内ROS的积累，进一步导致PI3K/Akt信号通路的抑制。最后，体内研究表明，普罗托品也抑制了异种移植物小鼠的肿瘤生长，没有明显的毒性。 结论：Protopine可作为治疗肝癌的潜在药物[2]。

蛋白质印迹分析[2]
细胞类型： HepG2、Huh7
测试浓度： 10、20、40 μM
孵育时间： 24小时
实验结果：诱导caspase-3和caspase-9裂解。 Bcl-2 和 Bcl-xl 水平降低。诱导线粒体蛋白细胞色素 c 释放到细胞质中。

Animal/Disease Models: 5-Hydroxy-DL-tryptophan (5-HTP)-induced mouse model [3]
Doses: 5, 10, 20 mg/kg
Route of Administration: intraperitoneal (ip) injection
Experimental Results: Increased 5-HTP-induced head Number of hemispheric twitch responses (HTR). Reduce the immobility time tested in the Tail Suspension Test (TST).

---

The protopine isolated from a Chinese herb Dactylicapnos scandens Hutch was identified as an inhibitor of both serotonin transporter and noradrenaline transporter in vitro assays. 5-hydroxy-DL-tryptophan(5-HTP)-induced head twitch response (HTR) and tail suspension test were adopted to study whether protopine has anti-depression effect in mice using reference antidepressant fluoxetine and desipramine as positive controls. In HTR test, protopine at doses of 5, 10, 20 mg/kg dose dependently increase the number of 5-HTP-induced HTR. Protopine at doses of 3.75 mg/kg, 7.5 mg/kg and 30 mg/kg also produces a dose-dependent reduction in immobility in the tail suspension test. The present results open up new possibilities for the use of protopine in the treatment of mood disorders, such as mild and moderate states of depression.[3]

---

Protopine, an isoquinoline alkaloidis, is known to produce many effects such as vasodilation, down-regulation of glutamate levels in brain and decrease of intracellular calcium. However, so far there is no report on the effect of protopine in cerebral ischaemia. In this study, the effect of protopine on the focal cerebral ischaemia was investigated in rats. Male Sprague-Dawley rats were divided into five groups: sham-operated group, vehicle-treated group and three doses of protopine-treated groups (0.98, 1.96 and 3.92 mg/kg). Protopine was intraperitoneally administered to rats once daily for 3 days prior to the ischaemia and 0.9% normal saline to rats in the vehicle-treated group in the same pattern. Rats in the sham-operated group were given 0.9% normal saline without the ischaemia. The focal cerebral ischaemia was induced by the middle cerebral artery occlusion for 24 hr via the intraluminal filament technique. The results showed that pre-treatment with protopine reduced the cerebral infarction ratio and serum lactate dehydrogenase activity, and improved the ischaemia-induced neurological deficit score and histological changes of brain in a dose-dependent manner. The further studies demonstrated that protopine increased superoxide dismutase activity in serum, and decreased total calcium and terminal deoxynucleotidyl transferase-mediated dUTP nick end labelling (TUNEL)-positive cells in the ischaemic brain tissue in the middle cerebral artery occlusion rats. The results indicate that protopine is able to produce an effective protection on the injury caused by the focal cerebral ischaemia in rats possibly through the multiple effects of calcium antagonism, antioxidation and depression of cell apoptosis.[4]

Absorption, Distribution and Excretion
Xiang-Fu-Si-Wu Decoction (XFSWD) has been widely used to treat primary dysmenorrhea in clinical practice for hundreds of years and shown great efficacy. One fraction of XFSWD, which was an elution product by macroporous adsorption resin from aqueous extract solution with 60% ethanol (XFSWE), showed great analgesic effect. The present study was conducted to investigate the possible pharmacokinetic and tissue distribution profiles of four major bioactive constituents (berberine, protopine, tetrahydrocoptisine and tetrahydropalmatine) after oral administration of XFSWE in dysmenorrheal symptom rats, and to compare the difference between normal and dysmenorrheal symptom rats. Estradiol benzoate and oxytocin were used to produce dysmenorrheal symptom rat model. The experimental period was seven days. At the final day of experimental period, both normal and dysmenorrheal symptom rats were orally administrated with XFSWE, and then the blood and tissues samples were collected at different time points. Berberine, protopine, tetrahydrocoptisine and tetrahydropalmatine in blood and tissue samples were determined by LC-MS/MS. Pharmacokinetic parameters were calculated from the plasma concentration-time data using non-compartmental methods. The differences of pharmacokinetic parameters among groups were tested by one-way analysis of variance (ANOVA). There were statistically significant differences (P<0.05) in Cmax, Tmax, AUC(0-t), AUC(0-infinity), MRT(0-t), MRT(0-infinity) and CL/F between normal and dysmenorrheal symptom rats that orally administered with same dosage of XFSWE. In tissue distribution study, the results showed that the overall trend was C(Spleen)>C(Liver)>C(Kidney)>C(Uterus)>C(Heart)>C(Lung)>C(Ovary)>C(Brain)>C(Thymus), C(M-60 min)>C(M-120 min)>C(M-30 min)>C(C-60 min)>C(C-120 min)>C(C-30 min). The contents of protopine in liver, spleen and uterus were more than that in other tissues of dysmenorrheal symptom rats. Compared to normal rats, partial contents of the compounds in dysmenorrheal symptom rats' tissues at different time points had significant difference (P<0.05). This study was the first report about pharmacokinetic and tissue distribution investigation in dysmenorrheal symptom animals. The results indicated that berberine, protopine, tetrahydrocoptisine and tetrahydropalmatine have higher uptake and slower elimination in the rats with dysmenorrheal syndrome, which suggests that the rate and extent of drug metabolism were altered in dysmenorrheal syndrome rats. And the results also demonstrated that berberine, protopine and tetrahydropalmatine in normal and dysmenorrheal symptom rats had obvious differences in some organs and time points, suggesting that the blood flow and perfusion rate of the organ were altered in dysmenorrheal symptom animals.

---

Metabolism / Metabolites
Eschscholtzia californica preparations are in use as phytopharmaceuticals and as herbal drugs. Studies are described on the metabolism and the toxicological analysis of the Eschscholtzia californica alkaloids californine and protopine in rat urine using gas chromatography-mass spectrometry. ... Protopine ... undergoes extensive demethylenation of the 2,3-methylenedioxy group followed by catechol-O-methylation. All phenolic hydroxy metabolites were found to be partly conjugated. The authors' systematic toxicological analysis procedure using full-scan gas chromatography-mass spectrometry after acid hydrolysis, liquid-liquid extraction and microwave-assisted acetylation allowed the detection of the main metabolites of californine and protopine in rat urine after a dose which should correspond to that of drug users. Therefore, use of Eschscholtzia californica preparations should also be detectable in human urine by the authors' systematic toxicological analysis procedure.

Toxicity Summary
IDENTIFICATION AND USE: Protopine is a solid. It is used as medication. HUMAN EXPOSURE AND TOXICITY: Using gene reporter assays performed in transiently transfected HepG2 cells, it was demonstrated that the induction of CYP1A1 expression by protopine was associated with mild or negligible activation of the aryl hydrocarbon receptor. CYP1A mRNA levels induced by protopine in both HepG2 cells and human hepatocytes did not result in elevated CYP1A protein or activity levels. ANIMAL STUDIES: Protopine showed an ability to enhance gamma-aminobutyric acid binding to rat brain synaptic membrane receptors in in vitro radiolabeling studies. Protopine has antiarrhythmic effects and may directly inhibit rapid electrical activity of cardiac cells.
Protopine has been found to inhibit histamine H1 receptors and platelet aggregation, and acts as an analgesic. It is one of the compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Protopine can selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Classical antihistaminics antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. Protopine can also function as platelet aggregation inhibitors which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Protopine inhibits the contractility of isolated cardiac papillary muscles and the proliferation of vascular smooth muscle cells induced by endothelin. It also shortens action potential duration and prolongs the effective refractory period in guinea pig cardiac papillary muscles. The protective effect on rat heart from ischemia_reperfusion damage and the relaxation of rat thoracic aorta induced by protopine have been related to the inhibition of Ca2+ influx through both voltage- and receptor-operated Ca2+ channels. Protopine has been the focus of a large number of biological studies in which they both exhibited, for instance, anti-parasitic activity and only weak cytotoxicity in comparison with other types of isoquinoline alkaloids. Protopine was found to be cytoprotective against oxidative stress induced cell death in vitro. The alkaloid was shown to have anti-arrhythmic, anti-thrombotic, anti-inflammatory, and hepatoprotective effects in animal models. The biological activity of protopine may be associated with its ability to inhibit calcium, sodium, and potassium channels. (PMID:15588728; PMID:21419197; L2104)

---

Interactions
The antiarrhythmic effects of protopine on experimental arrhythmia were studied in various animals. Protopine elevated the dose of aconitine needed to induce VP, VT, and VF in rats and increased the dose of strophanthin (strophanthine K) that induced VP in guinea pigs. It also shortened the duration of central arrhythmia induced by aconitine and the duration of arrhythmia induced by benzene-epinephrine (adrenaline) in rats. It prevented rats and mice from developing arrhythmia induced by intravenous calcium chloride and inhalation of chloroform, respectively. In rabbits, the drug raised VFT. It was concluded that protopine has antiarrhythmic effects and may directly inhibit rapid electrical activity of cardiac cells.

---

Non-Human Toxicity Values
LD50 Guinea pig ip 116 mg/kg
LD50 Guinea pig oral 237 mg/kg
LD50 Mouse ip 482 mg/kg

[1]. Protopine from Corydalis ternata has anticholinesterase and antiamnesic activities. Planta Med. 1999 Apr;65(3):218-21.

[2]. Protopine triggers apoptosis via the intrinsic pathway and regulation of ROS/PI3K/Akt signalling pathway in liver carcinoma. Cancer Cell Int. 2021 Jul 27;21(1):396.

[3]. Protopine inhibits serotonin transporter and noradrenaline transporter and has the antidepressant-like effect in mice models. Neuropharmacology. 2006 Jun;50(8):934-40.

[4]. Protective effect of protopine on the focal cerebral ischaemic injury in rats. Basic Clin Pharmacol Toxicol. 2007 Aug;101(2):85-9.

Protopine is a dibenzazecine alkaloid isolated from Fumaria vaillantii. It has a role as a plant metabolite.
Protopine has been reported in Corydalis solida, Corydalis ternata, and other organisms with data available.
Protopine is a benzylisoquinoline alkaloid occurring in opium poppies and other plants of the family papaveraceae. It has been found to inhibit histamine H1 receptors and platelet aggregation, and acts as an opioid analgesic.
See also: Sanguinaria canadensis root (part of); Chelidonium majus flowering top (part of).

---

Therapeutic Uses
Analgesics, Opioid; Histamine H1 Antagonists; Platelet Aggregation Inhibitors
/EXPL THER/ ... In the present study, we studied the anticancer proliferation and adhesion effects of five alkaloids which were isolated from Corydalis yanhusuo. MTT dose response curves, cell migration assay, cell invasion assay, as well as three types of cell adhesive assay were performed on MDA-MB-231 human breast cancer cells. The mechanism of the compounds on inhibiting heterotypic cell adhesion were further explored by determining the expression of epidermal growth factor receptor (EGFR), Intercellular adhesion molecule 1 (ICAM-1), alphav-integrin, beta1-integrin and beta5-integrin by western blotting assay. In five tested alkaloids, only protopine exhibited anti-adhesive and anti-invasion effects in MDA-MB-231 cells, which contributed to the anti-metastasis effect of Corydalis yanhusuo. The results showed that after treatment with protopine for 90 min, the expression of EGFR, ICAM-1, alphav-integrin, beta1-integrin and beta5-integrin were remarkably reduced. The present results suggest that protopine seems to inhibit the heterotypic cell adhesion between MDA-MB-231 cells, and human umbilical vein endothelial cells by changing the expression of adhesive factors.
/EXPL THER/ ... In this study, we investigated whether protopine derived from Hypecoum erectum L could suppress lipopolysaccharide (LPS)-induced inflammatory responses in murine macrophages (Raw 264.7 cells). Protopine was found to reduce nitric oxide (NO), cyclooxygenase-2 (COX-2), and prostaglandin E(2) (PGE(2)) production by LPS-stimulated Raw 264.7 cells, without a cytotoxic effect. Pre-treatment of Raw 264.7 cells with protopine reduced the production of pro-inflammatory cytokines. These inhibitory effects were caused by blocking phosphorylation of mitogen-activated protein kinases (MAP kinases) and also blocking activation of a nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB).
/EXPL THER/ In this study, we investigated the anticancer effect of protopine on human hormone-refractory prostate cancer (HRPC) cells. Protopine exhibited an anti-proliferative effect by induction of tubulin polymerization and mitotic arrest, which ultimately led to apoptotic cell death. The data suggest that protopine increased the activity of cyclin-dependent kinase 1 (Cdk1)/cyclin B1 complex and that contributed to cell apoptosis by modulating mitochondria-mediated signaling pathways, such as Bcl-2 phosphorylation and Mcl-1 down-regulation. In conclusion, the data suggest that protopine is a novel microtubule stabilizer with anticancer activity in HRPC cells through apoptotic pathway by modulating Cdk1 activity and Bcl-2 family of proteins.
For more Therapeutic Uses (Complete) data for PROTOPINE (12 total), please visit the HSDB record page.

C20H19NO5

353.374

353.126

130-86-9

Protopine hydrochloride;6164-47-2

4970

White to off-white solid powder

1.3±0.1 g/cm3

547.5±49.0 °C at 760 mmHg

211ºC

284.9±29.8 °C

0.0±1.5 mmHg at 25°C

1.613

3.76

57.23

0

6

0

26

542

0

GPTFURBXHJWNHR-UHFFFAOYSA-N

InChI=1S/C20H19NO5/c1-21-5-4-13-7-18-19(25-10-24-18)8-14(13)16(22)6-12-2-3-17-20(15(12)9-21)26-11-23-17/h2-3,7-8H,4-6,9-11H2,1H3

15-methyl-7,9,19,21-tetraoxa-15-azapentacyclo[15.7.0.04,12.06,10.018,22]tetracosa-1(17),4,6(10),11,18(22),23-hexaen-3-one

Fumarine; Biflorine; Corydinine; Fumarine; Biflorine; Macleyine; Protopin; Hypercorine; Protopine

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~12.5 mg/mL (~35.37 mM)

配方 1 中的溶解度: ≥ 1.47 mg/mL (4.16 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将100 μL 14.7 mg/mL澄清DMSO储备液加入400 μL PEG300中，混匀；然后向上述溶液中加入50 μL Tween-80，混匀；加入450 μL生理盐水定容至1 mL。
*生理盐水的制备：将 0.9 g 氯化钠溶解在 100 mL ddH₂O中，得到澄清溶液。

---

配方 2 中的溶解度: ≥ 1.25 mg/mL (3.54 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 12.5 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中，混匀。
*20% SBE-β-CD 生理盐水溶液的制备（4°C，1 周）：将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中，得到澄清溶液。

---

View More

配方 3 中的溶解度: ≥ 1.25 mg/mL (3.54 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加，逐一添加), 澄清溶液。
例如，若需制备1 mL的工作液，可将 100 μL 12.5 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。